Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg) (CovidSurg)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
There is an urgent need to understand the outcomes of COVID-19 infected patients who undergo surgery. Capturing real-world data and sharing international experience will inform the management of this complex group of patients who undergo surgery throughout the COVID-19 pandemic, improving their clinical care.
The primary aim of the study is to determine 30-day mortality in patients with COVID-19 infection who undergo surgery. In doing so, this will inform future risk stratification, decision making, and patient consent.
CovidSurg is an investigator-led, non-commercial, non-interventional study is extremely low risk, or even zero risk. This study does not collect any patient identifiable information (including no dates) and data will not be analysed at hospital-level.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Aneel Bhangu
- Phone Number: +44 1216272949
- Email: A.A.Bhangu@bham.ac.uk
Study Contact Backup
- Name: Dmitri Nepogodiev
- Phone Number: +44 1216272949
- Email: D.Nepogodiev@bham.ac.uk
Study Locations
-
-
-
Madrid, Spain
- Recruiting
- Hospital del Henares
-
Principal Investigator:
- Ana Minaya-Bravo
-
Contact:
- Ana Minaya-Bravo
- Email: Ana-minaya@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergoing ANY type of surgery in an operating theatre, this includes obstetrics
AND
- The patient had COVID-19 infection either at the time of surgery or within 30 days of surgery, based on
(i) positive COVID-19 lab test or computed tomography (CT) chest scan
OR
(ii) clinical diagnosis (no COVID-19 lab test or CT chest performed)
Exclusion Criteria:
- If COVID-19 infection is diagnosed >30 days after discharge, the patient should not be included.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cohort 1
Patients with COVID-19 infection undergoing surgery
|
Emergency or elective surgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
30-day mortality
Time Frame: 30 days
|
Death up to 30-days post surgery
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
7-day mortality
Time Frame: 7 days post surgery
|
Death up to 7-days post surgery
|
7 days post surgery
|
|
30-day reoperation
Time Frame: Up to 30-days post surgery
|
Reoperation up to 30-days post surgery
|
Up to 30-days post surgery
|
|
Postoperative ICU admission
Time Frame: Up to 30 days post surgery
|
Admission to ICU post surgery
|
Up to 30 days post surgery
|
|
Postoperative respiratory failure
Time Frame: Up to 30 days post surgery
|
Respiratory failure post surgery
|
Up to 30 days post surgery
|
|
Postoperative acute respiratory distress syndrome (ARDS)
Time Frame: Up to 30 days post surgery
|
Acute respiratory distress syndrome post surgery
|
Up to 30 days post surgery
|
|
Postoperative sepsis
Time Frame: Up to 30 days post surgery
|
Sepsis post surgery
|
Up to 30 days post surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- COVIDSurg Collaborative. Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study. BMJ Open. 2021 Nov 30;11(11):e050830. doi: 10.1136/bmjopen-2021-050830.
- Seeliger B, Philouze G, Cherkaoui Z, Felli E, Mutter D, Pessaux P. Acute abdomen in patients with SARS-CoV-2 infection or co-infection. Langenbecks Arch Surg. 2020 Sep;405(6):861-866. doi: 10.1007/s00423-020-01948-2. Epub 2020 Jul 27.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CS-20200324
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.